A Phase I study of RSR13, a radiation-enhancing hemoglobin modifier: Tolerance of repeated intravenous doses and correlation of pharmacokinetics with pharmacodynamics

International Journal of Radiation Oncology Biology Physics

Volumn 49, Issue 4, 2001, Pages 1133-1139

  Kavanagh, Brian D ^a   Khandelwal, Shiv R ^a   Schmidt Ullrich, Rupert K ^a   Roberts, John D ^a   Shaw, Edward G ^b   Pearlman, Andrew D ^b   Venitz, Jurgen ^a   Dusenbery, Kathryn E ^c   Abraham, Donald J ^a   Gerber, Michael J ^d  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d Allos Therapeutics Inc   (United States)

Author keywords

Allosteric modifier; Hemoglobin; Hypoxia; Radiosensitizer; RSR13

Indexed keywords

CORTICOSTEROID; EFAPROXIRAL; OXYGEN; RADIOSENSITIZING AGENT;

ADULT; AGED; ARTERIAL OXYGEN SATURATION; ARTICLE; BRAIN EDEMA; CANCER; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG TOLERANCE; DRUG URINE LEVEL; DYSPNEA; ERYTHROCYTE LEVEL; FATIGUE; FEMALE; FLUID RETENTION; GLIOMA; HEADACHE; HUMAN; HYPOXEMIA; MALE; NAUSEA; OXYGEN AFFINITY; PALLIATIVE THERAPY; PERFORMANCE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE; RADIOSENSITIZATION; RECURRENT CANCER; SEIZURE; TONOMETRY;

ADULT; AGED; AGED, 80 AND OVER; ANILINE COMPOUNDS; CELL HYPOXIA; ERYTHROCYTES; FEMALE; HEMOGLOBIN A; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; OXYGEN; PARTIAL PRESSURE; PROPIONIC ACIDS; RADIATION-SENSITIZING AGENTS; RADIOTHERAPY DOSAGE;

EID: 0035869709     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(00)01532-7     Document Type: Article

References (27)

1. Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy
2. Intratumoral pO2 predicts survival in advanced cancer of the uterine cervix
3. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck
4. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck
5. The in vivo radiation response of an experimental tumor; the effect of exposing tumor-bearing mice to a reduced oxygen environment prior to but not during irradiation
6. Tumor radiosensitization through reductions in hemoglobin affinity
7. The influence of haemoglobin affinity for oxygen on tumour radiosensitivity
8. Chlorophenoxy acetic acid derivatives as hemoglobin modifiers and tumor radiosensitizers
9. The modification of hemoglobin affinity for oxygen and tumor radiosensitivity by antilipidemic drugs
10. Allosteric modifiers of hemoglobin. 1. Design, synthesis, testing, and structure-allosteric activity relationship of novel hemoglobin oxygen affinity decreasing agents
11. Allosteric modifiers of hemoglobin; 2-[4-[[(3, 5-disubstituted anilino) carbonyl] methyl] phenoxy]-2-methylpropionic acid derivatives that lower the oxygen affinity of hemoglobin in red cell suspensions, in whole blood, and in vivo in rats
12. Allosteric modifiers of hemoglobin. 2. Crystallographically determined binding sites and hydrophobic binding/interaction analysis of novel hemoglobin oxygen effectors
13. Increased radiation response of FsaII fibrosarcomas in C3H mice following administration of an allosteric effector of hemoglobin-oxygen affinity
14. RSR13; Effects on tumor oxygenation and response to therapy
15. RSR13, a synthetic allosteric modifier of hemoglobin, as an adjunct to radiotherapy; Preliminary studies with EMT6 cells and tumors and normal tissues in mice
16. RSR13, an allosteric effector of hemoglobin, and carbogen radiosensitize FSAII and SCCVII tumors in C3H mice
17. Recursive partitioning (RPA) analysis of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials
18. Phase I trial to determine the safety, pharmacodynamics, and pharmacokinetics of RSR13, a novel radioenhancer, in newly diagnosed glioblastoma multiforme
19. Theoretical analysis of optimal P50
20. Optimal hematologic variables for oxygen transport, including P50, hemoglobin cooperativity, hematocrit, acid-base status, and cardiac function
21. Analysis of the effects of oxygen supply and demand on hypoxic fraction in tumors
22. Insensitivity of VO2max to hemoglobin-P50 at sea level and altitude
23. Effect of carboxyhemoglobin on tumor oxygen unloading capacity in patients with squamous cell carcinoma of the head and neck